Viktor A. Adalsteinsson

This study evaluates how preanalytical factors affect liquid biopsy in canine cancer models, finding that tumor content and metrics vary by blood draw location and cancer type.

MEDUSA improves sequencing accuracy by minimizing DNA duplex resynthesis during library preparation, achieving lower residual SNV frequency in genomic and cell-free DNA.

This paper identifies molecular features of monoclonal antibodies that enhance ctDNA detection by increasing its concentration in blood.

The paper introduces aMAPP, a PCR-based method to enrich methylated or unmethylated CpGs, enabling sensitive detection of DMRs in cancer samples with low DNA input.

This study benchmarks six duplex sequencing technologies to evaluate their performance in detecting somatic mutations across different genomic contexts and tissue types.

Methyl-CODEC enables simultaneous methylation and duplex sequencing, improving mutation detection and distinguishing methylated Cs from mutations.

DirectHRD is a whole-genome sequencing-based classifier that improves HRD detection sensitivity in low tumor fraction samples.

FinaleMe predicts DNA methylation and tissues-of-origin from plasma whole-genome sequencing by using a non-homogeneous Hidden Markov Model.

A DNA-binding agent increases cfDNA levels in blood, improving ctDNA detection and cancer sensitivity in mice.

A nanoparticle priming agent increases cfDNA levels in blood, improving ctDNA detection sensitivity in tumor-bearing mice.

The paper identifies DNA strand resynthesis as a source of false mutations in sequencing and introduces Duplex-Repair to reduce this error, improving sequencing accuracy.

MAESTRO enables efficient and accurate tracking of thousands of low-frequency mutations with reduced sequencing, improving mutation testing in cancer and liquid biopsies.